AstraZeneca just smashed Q2 earnings, beating profit forecasts and reaffirming its bold 2030 goal of $80 billion in revenue. Core earnings are on track for low double-digit growth by 2026, fueled by a 15% surge in cancer drugs and 8% gains in rare disease treatments. China’s market dipped 13% due to generics and policy shifts, but the CEO remains bullish, highlighting a robust pipeline with over 20 major updates coming in 18 months. The company is also ramping up in weight loss with oral GLP-1 trials to challenge Novo Nordisk and Eli Lilly, while boosting its respiratory drug forecast to $5 billion. A surprising twist? Iran’s instability is hiking logistics costs — proving global events ripple even through pharma giants.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
